Mavyret addendum—ABBV’s new 2021 sales guidance of $1.9B (lowered from $2.0B) implies about $500M of Mavyret sales in 3Q21 and 4Q21. (1H21 Mavyret sales were $856M.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”